<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="184587">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691015</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000597130</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2007-127</secondary_id>
    <secondary_id>GENZ-WSU-2007-127</secondary_id>
    <nct_id>NCT00691015</nct_id>
  </id_info>
  <brief_title>Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant</brief_title>
  <official_title>A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy
      before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
      It may also stop the patient's immune system from rejecting the donor's stem cells. The
      donated stem cells may replace the patient's immune cells and help destroy any remaining
      cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can
      also make an immune response against the body's normal cells. Giving tacrolimus, sirolimus,
      and antithymocyte globulin before and after transplant may stop this from happening.

      PURPOSE: This phase II trial is studying the side effects of giving sirolimus together with
      tacrolimus and antithymocyte globulin and to see how well it works in preventing
      graft-versus-host disease in patients with hematologic cancer who are undergoing donor stem
      cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the incidence and severity of acute graft-versus-host disease (GVHD) after
           HLA-matched or -mismatched unrelated donor peripheral blood stem cell transplantation
           (PBSCT) in patients with hematologic malignancies treated with immunosuppressive
           therapy comprising sirolimus, tacrolimus, and anti-thymocyte globulin as GVHD
           prophylaxis.

        -  To determine the safety of this regimen in these patients at 6 months after PBSCT.

      Secondary

        -  To determine the time to engraftment (i.e., platelet and absolute neutrophil recovery)
           in patients treated with this regimen.

        -  To determine the length of hospital stay of these patients within 100 days after PBSCT.

        -  To determine the incidence of infections, including CMV and EBV reactivation and
           post-transplant lymphoproliferative disorders, in patients treated with this regimen.

        -  To determine the incidence of thrombotic microangiopathy and veno-occlusive disease in
           patients treated with this regimen.

        -  To determine the incidence of chronic GVHD in patients treated with this regimen.

        -  To determine the overall and disease-free survival of these patients at 2 years after
           PBSCT.

        -  To determine the Karnofsky performance status of these patients at baseline and at
           various time points after PBSCT.

        -  To conduct immunocorrelative studies prior to and at various time points after PBSCT.

      OUTLINE:

        -  Conditioning regimen: Patients receive 1 of 6 conditioning regimens between days -9 and
           -3, based on diagnosis and the treating physician's preference regarding regimen
           intensity.

             -  Regimen I: Patients receive fludarabine phosphate IV and busulfan IV.

             -  Regimen II: Patients undergo total body irradiation (TBI) twice daily for 8
                fractions and receive etoposide IV.

             -  Regimen III: Patients undergo TBI once or twice daily for 11 fractions and receive
                cyclophosphamide IV.

             -  Regimen IV: Patients undergo TBI and receive fludarabine phosphate IV and busulfan
                IV.

             -  Regimen V: Patients receive carmustine IV, etoposide IV, cytarabine IV, and
                melphalan IV. Some patients also receive rituximab IV.

             -  Regimen VI: Patients receive fludarabine phosphate IV and melphalan IV. Some
                patients also undergo TBI.

        -  Allogeneic peripheral blood stem cell transplantation: Patients undergo filgrastim
           (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.

        -  Graft-versus-host disease prophylaxis (GVHD): Patients receive tacrolimus IV
           continuously over 24 hours or orally and sirolimus orally beginning on day -3 and
           continuing until day 30 or day 90, followed by a taper in the absence of GVHD. Patients
           also receive anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.

      Blood samples are obtained at baseline and periodically during study for correlative
      biomarker studies. Samples are analyzed by T-cell immunophenotyping, absolute subset number
      quantification, and multi-parameter flow cytometry for evaluation of immune reconstitution,
      T-cell differentiation status, NK-cell recovery, allo-reactivity of donor T-cells after
      transplantation, and regulatory T-cell reconstitution.

      After completion of study therapy, patients are followed periodically for up to 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of acute graft-versus-host disease (GVHD)</measure>
    <time_frame>Within 100 days after donor peripheral blood stem cell transplantation (PBSCT) as assessed by Glucksberg criteria</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as defined by serious adverse events and adverse events related to study treatment.</measure>
    <time_frame>Within 6 months after PBSCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD.</measure>
    <time_frame>Within 2 years after PBSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to engraftment (i.e., absolute neutrophil recovery [ANC &gt; 1,500/mm³] and platelet recovery [platelet count &gt; 25,000/mm³])</measure>
    <time_frame>At screening, post transplant, 30, 60, 90 &amp; 180 days after PBSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and disease-free survival.</measure>
    <time_frame>At 2 years after PBSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay.</measure>
    <time_frame>Within 100 days after PBSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections, including bacterial, fungal, and viral infections (i.e., CMV and EBV reactivation, including post-transplant lymphoproliferative disorders)</measure>
    <time_frame>Within 6 months after PBSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thrombotic microangiopathy</measure>
    <time_frame>Within 100 days after PBSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky performance status</measure>
    <time_frame>At baseline and at 100 days, 6 months, 1 year, and 2 years after PBSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers and immunocorrelative studies (i.e., T-cell, B-cell, NK-cell, regulatory T-cell, and allo-reactive T-cell quantitation studies by flow cytometry)</measure>
    <time_frame>At 30, 60, 90, and 180 days after PBSCT</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <arm_group>
    <arm_group_label>Conditioning regimen I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine phosphate IV and busulfan IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conditioning regimen II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo total body irradiation (TBI) twice daily for 8 fractions and receive etoposide IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conditioning regimen III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo TBI once or twice daily for 11 fractions and receive cyclophosphamide IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conditioning regimen IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo TBI and receive fludarabine phosphate IV and busulfan IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conditioning regimen V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive carmustine IV, etoposide IV, cytarabine IV, and melphalan IV. Some patients also receive rituximab IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conditioning regimen VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine phosphate IV and melphalan IV. Some patients also undergo TBI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Conditioning regimen V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Conditioning regimen I</arm_group_label>
    <arm_group_label>Conditioning regimen IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Conditioning regimen V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Conditioning regimen III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Conditioning regimen V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Conditioning regimen II</arm_group_label>
    <arm_group_label>Conditioning regimen V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Conditioning regimen I</arm_group_label>
    <arm_group_label>Conditioning regimen IV</arm_group_label>
    <arm_group_label>Conditioning regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Conditioning regimen V</arm_group_label>
    <arm_group_label>Conditioning regimen VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Given once or twice daily</description>
    <arm_group_label>Conditioning regimen II</arm_group_label>
    <arm_group_label>Conditioning regimen III</arm_group_label>
    <arm_group_label>Conditioning regimen VI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of a hematological malignancy, including any of the following:

               -  Non-Hodgkin lymphoma in complete remission (CR) or partial remission (PR)

               -  Hodgkin lymphoma in CR or PR

               -  Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) meeting
                  either of the following criteria:

                    -  In CR

                    -  Not in CR and meets the following criteria:

                         -  Bone marrow blast &lt; 20% within 4 weeks of transplantation

                         -  Peripheral blood absolute blast count &lt; 500 per microliter on the day
                            of initiating conditioning therapy

               -  Myelodysplastic syndromes, treated or untreated

               -  Chronic myeloid leukemia in chronic phase or accelerated phase

               -  Multiple myeloma in CR or PR

               -  Chronic lymphocytic leukemia in second or greater CR or PR

               -  Myelofibrosis or other myeloproliferative disorders meeting the following
                  criteria:

                    -  Bone marrow blasts &lt; 20% within 4 weeks of transplantation

                    -  Peripheral blood absolute blast count &lt; 500 per microliter on the day of
                       initiating conditioning therapy

                    -  Patients with ascites not allowed

          -  No prior bone marrow or ex vivo engineered or processed graft (i.e., CD34+
             enrichment, T-cell depletion, etc)

          -  Scheduled to undergo peripheral blood stem cell transplantation from a suitable
             HLA-matched or -mismatched unrelated donor, as determined by treating physician

               -  High resolution molecular HLA typing is required for HLA class I and II

               -  No more than one antigen or allele mismatch

          -  No documented uncontrolled CNS disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2

          -  Karnofsky PS 60-100%

          -  Creatinine clearance &gt; 50 mL/min

          -  Bilirubin &lt; 3 times upper limit of normal (ULN)

          -  ALT and AST &lt; 3 times ULN

          -  LVEF &gt; 50%

          -  FVC, FEV_1, or DLCO &gt; 50% predicted

               -  Patients on home oxygen not allowed

          -  Able to cooperate with oral medication intake

          -  HIV negative

          -  No active hepatitis B or hepatitis C

          -  No known contraindication to sirolimus, tacrolimus, or anti-thymocyte globulin

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaid Al-Kadhimi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 6, 2012</lastchanged_date>
  <firstreceived_date>June 4, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Zaid Al-Kadhimi</name_title>
    <organization>Barbara Ann Karmanos Cancer Institute</organization>
  </responsible_party>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL negative</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
